Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

HHS.gov
  • About HHS
  • Programs & Services
  • Grants & Contracts
  • Laws & Regulations

Breadcrumb

  1. Home
  2. About
  3. News
  4. Statement from HHS Secretary Xavier Becerra on the Authorization of Protein-Based Novavax COVID-19 Vaccine
  • News
  • Blog
  • HHS Live
  • Podcasts
  • Media Guidelines for HHS Employees
FOR IMMEDIATE RELEASE
July 19, 2022
Contact: HHS Press Office
202-690-6343
media@hhs.gov

Statement from HHS Secretary Xavier Becerra on the Authorization of Protein-Based Novavax COVID-19 Vaccine

In response to the Centers for Disease Control and Prevention’s (CDC’s) recommendation to make the protein-based Novavax COVID-19 vaccine available to the American people, U.S. Department of Health and Human Services Secretary Xavier Becerra issued the statement below on the CDC’s recommendation of this additional COVID-19 vaccine option. CDC’s recommendation followed the Food and Drug Administration’s (FDA’s) authorization of the Novavax COVID-19 vaccine for emergency use in individuals 18 years and older as a primary vaccination series against COVID-19, and an Advisory Community on Immunization Practices’ (ACIP’s) recommendation for use of this vaccine.

“The Novavax vaccine is one more important tool in our COVID-19 response, and it marks one more way we’re working to make safe and effective vaccines available to the public,” said Secretary Becerra. “Based on CDC and FDA action, the Novavax vaccine will be available for people age 18 and up who require or prefer a protein-based vaccine. We will leave no stone unturned to protect people against COVID-19 and save lives.”

The Novavax COVID-19 vaccine is designed and manufactured differently than the mRNA COVID-19 vaccines. The Novavax COVID-19 vaccine contains SARS-CoV-2 recombinant spike protein, which is also known as an “antigen” of the SARS-CoV-2 virus, in combination with an adjuvant, which enhances the immune system response to the spike protein.

FDA-approved protein-based vaccines have been used widely for decades; examples of more recently approved vaccines that contain a purified protein combined with an adjuvant include vaccines to prevent hepatitis B and shingles. The Novavax COVID-19 vaccine offers an option to individuals who may be allergic to a component in the mRNA vaccines, or who have a personal preference for receiving a vaccine other than an mRNA-based vaccine.

###
Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.
Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.
Last revised: July 19, 2022

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up

Subscribe to RSS

Receive latest updates

Subscribe to our RSS

Related News Releases

  • Readout of HHS Secretary Becerra’s Meeting with National Public Health Leaders on Vaccines for COVID, flu and RSV

  • Letter to COVID-19 therapeutics manufacturers, distributors, pharmacies and the health care payer community.

  • Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics

Related Blog Posts

  • HHS Blog thumbnail

    Driving Long COVID Innovation with Health+ Human-Centered Design

  • Assistant Secretary for Global Affairs Loyce Pace

    U.S. Summary of the 75th World Health Assembly

  • HHS Blog thumbnail

    Working Day or Night, NDMS Teams Deploy to Support Healthcare Facilities and Save Lives in Communities Overwhelmed by COVID-19: “We are NDMS…That’s What We do”

Media Inquiries

For general media inquiries, please contact media@hhs.gov.

Content created by Assistant Secretary for Public Affairs (ASPA)
Content last reviewed July 19, 2022
Back to top
  • Contact HHS
  • Careers
  • HHS FAQs
  • Nondiscrimination Notice
  • HHS Archive
  • Accessibility
  • Privacy Policy
  • Viewers & Players
  • Budget/Performance
  • Inspector General
  • Web Site Disclaimers
  • EEO/No Fear Act
  • FOIA
  • The White House
  • USA.gov
  • Vulnerability Disclosure Policy

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
HHS Logo

HHS Headquarters

200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free Call Center: 1-877-696-6775​